I'm sure Dew and others who follow the space much more closely will give a lot better read. To me the results don't look as good (granted its not a head to head study) AND you have a longer treatment so unless the VRTX rash scares a lot of docs away I would think VRTX is the preferred treatment (in treatment naive at least).
A sign that Boceprevir could be heading for a bumpy ride is the contention of MRK’s CMO on today’s CC that “treatment of anemia with EPO is an accepted part of HCV therapy.”
Market Data 
Markets 
AI
